Sotatercept for the Treatment of Pulmonary Arterial Hypertension
RCT (n=106) found that treatment with sotatercept a novel fusion protein, that binds activins and growth differentiation factors resulted in a reduction in pulmonary vascular resistance in patients receiving background therapy at week 24.
Source:
New England Journal of Medicine
SPS commentary:
At 24 weeks, the least-squares mean difference between the sotatercept 0.3-mg and 0.7mg groups and the placebo group in the secondary outcome measure of change from baseline in 6-minute walk distance was 29.4 m and 21.4 m, respectively.
An editorial notes that sotatercept is a first-in-class drug with excellent theoretical potential to rebalance the TGF-β system, and the results of this trial justifies the need for longer trials and inclusion of sicker patients. It suggests this is a propitious advance for this difficult and fatal disease.